Literature DB >> 30070758

Mucopolysaccharidosis III in Taiwan: Natural history, clinical and molecular characteristics of 28 patients diagnosed during a 21-year period.

Hsiang-Yu Lin1,2,3,4,5, Chih-Kuang Chuang3,6, Chung-Lin Lee2, Ru-Yi Tu3, Yun-Ting Lo7, Pao Chin Chiu8, Dau-Ming Niu9, Yi-Ya Fang3, Tzu-Lin Chen7, Fuu-Jen Tsai10, Wuh-Liang Hwu11, Shio Jean Lin12, Tung-Ming Chang13,14, Shuan-Pei Lin1,2,3,15.   

Abstract

Mucopolysaccharidosis type III (MPS III, Sanfilippo syndrome) has a variable age of onset and variable rate of progression. However, information regarding the natural history of this disorder in Asian populations is limited. A retrospective analysis was carried out for 28 patients with MPS III (types IIIA [n = 3], IIIB [n = 23], and IIIC [n = 2]; 15 males and 13 females; median age, 8.2 years; age range, 2.7-26.5 years) seen in six medical centers in Taiwan from January 1996 through October 2017. The median age at confirmed diagnosis was 4.6 years. The most common initial symptom was speech delay (75%), followed by hirsutism (64%) and hyperactivity (54%). Both z scores for height and weight were negatively correlated with age (r = -.693 and -0.718, respectively; p < .01). The most prevalent clinical manifestations were speech delay (100%) and intellectual disability (100%), followed by hirsutism (93%), hyperactivity (79%), coarse facial features (68%), sleep disorders (61%), and hepatosplenomegaly (61%). Ten patients (36%) had epilepsy, and the median age at the first seizure was 11 years. Thirteen patients (46%) experienced at least one surgical procedure. At the time of the present study, 7 of the 28 patients had passed away at the median age of 13.0 years. Molecular studies showed an allelic heterogeneity without clear genotype and phenotype correlations. MPS IIIB is the most frequent subtype among MPS III in the Taiwanese population. An understanding of the natural history of MPS III may allow early diagnosis and timely management of the disease facilitating better treatment outcomes.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  clinical manifestations; diagnosis; management; mucopolysaccharidosis III; natural history

Mesh:

Substances:

Year:  2018        PMID: 30070758     DOI: 10.1002/ajmg.a.40351

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  12 in total

1.  Natural History and Molecular Characteristics of Korean Patients with Mucopolysaccharidosis Type III.

Authors:  Min-Sun Kim; Aram Yang; Eu-Seon Noh; Chiwoo Kim; Ga Young Bae; Han Hyuk Lim; Hyung-Doo Park; Sung Yoon Cho; Dong-Kyu Jin
Journal:  J Pers Med       Date:  2022-04-21

2.  What Can We Learn from the Parents of Children Affected with Mucopolysaccharidosis Type III-A in Israel?

Authors:  Shiri Liber; Orna Staretz-Chacham; Mor Kishon; Ben Pode-Shakked; Odelia Chorin; Katya Kneller; Yair Anikster; Geto Mangisto; Ann Saada; Annick Raas-Rothschild
Journal:  Mol Syndromol       Date:  2021-12-15

Review 3.  Cardiac characteristics and natural progression in Taiwanese patients with mucopolysaccharidosis III.

Authors:  Hsiang-Yu Lin; Ming-Ren Chen; Shan-Miao Lin; Chung-Lieh Hung; Dau-Ming Niu; Tung-Ming Chang; Chih-Kuang Chuang; Shuan-Pei Lin
Journal:  Orphanet J Rare Dis       Date:  2019-06-13       Impact factor: 4.123

4.  Functional independence of Taiwanese patients with mucopolysaccharidoses.

Authors:  Chung-Lin Lee; Hsiang-Yu Lin; Chih-Kuang Chuang; Huei-Ching Chiu; Ru-Yi Tu; You-Hsin Huang; Wuh-Liang Hwu; Fuu-Jen Tsai; Pao-Chin Chiu; Dau-Ming Niu; Yann-Jang Chen; Mei-Chyn Chao; Tung-Ming Chang; Ju-Li Lin; Chia-Ying Chang; Yu-Chia Kao; Shuan-Pei Lin
Journal:  Mol Genet Genomic Med       Date:  2019-06-18       Impact factor: 2.183

5.  An At-Risk Population Screening Program for Mucopolysaccharidoses by Measuring Urinary Glycosaminoglycans in Taiwan.

Authors:  Hsiang-Yu Lin; Chung-Lin Lee; Yun-Ting Lo; Ru-Yi Tu; Ya-Hui Chang; Chia-Ying Chang; Pao Chin Chiu; Tung-Ming Chang; Wen-Hui Tsai; Dau-Ming Niu; Chih-Kuang Chuang; Shuan-Pei Lin
Journal:  Diagnostics (Basel)       Date:  2019-10-05

6.  Survival and diagnostic age of 175 Taiwanese patients with mucopolysaccharidoses (1985-2019).

Authors:  Hsiang-Yu Lin; Chung-Lin Lee; Chia-Ying Chang; Pao Chin Chiu; Yin-Hsiu Chien; Dau-Ming Niu; Fuu-Jen Tsai; Wuh-Liang Hwu; Shio Jean Lin; Ju-Li Lin; Mei-Chyn Chao; Tung-Ming Chang; Wen-Hui Tsai; Tzu-Jou Wang; Chih-Kuang Chuang; Shuan-Pei Lin
Journal:  Orphanet J Rare Dis       Date:  2020-11-07       Impact factor: 4.123

Review 7.  Epidemiology of Mucopolysaccharidoses Update.

Authors:  Betul Çelik; Saori C Tomatsu; Shunji Tomatsu; Shaukat A Khan
Journal:  Diagnostics (Basel)       Date:  2021-02-10

Review 8.  Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions.

Authors:  Jeremy Wolfberg; Keerthana Chintalapati; Shunji Tomatsu; Kyoko Nagao
Journal:  Diagnostics (Basel)       Date:  2020-08-04

Review 9.  Molecular Bases of Neurodegeneration and Cognitive Decline, the Major Burden of Sanfilippo Disease.

Authors:  Rachel Heon-Roberts; Annie L A Nguyen; Alexey V Pshezhetsky
Journal:  J Clin Med       Date:  2020-01-27       Impact factor: 4.241

10.  Hematopoietic stem cell transplantation in mucopolysaccharidosis type IIIA: A case description and comparison with a genotype-matched control group.

Authors:  Anja F Köhn; Lorenz Grigull; Marcel du Moulin; Sarah Kabisch; Luise Ammer; Cornelia Rudolph; Nicole M Muschol
Journal:  Mol Genet Metab Rep       Date:  2020-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.